[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
    "summary": "Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index shedding 0.6% a",
    "url": "https://finnhub.io/api/news?id=dd41dd3c8aaca394e675c47f16c0787ecc39fefde5743f6d648bb526cd62cab5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770670824,
      "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
      "id": 138789744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index shedding 0.6% a",
      "url": "https://finnhub.io/api/news?id=dd41dd3c8aaca394e675c47f16c0787ecc39fefde5743f6d648bb526cd62cab5"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?",
    "summary": "These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.",
    "url": "https://finnhub.io/api/news?id=a1363f03bc39b18d80b5e165a3eda3e6f33b011c1f1d105fb626feecaca2af95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770666600,
      "headline": "Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?",
      "id": 138693458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.",
      "url": "https://finnhub.io/api/news?id=a1363f03bc39b18d80b5e165a3eda3e6f33b011c1f1d105fb626feecaca2af95"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Escalates Fight Against Hims & Hers",
    "summary": "The Danish drugmaker’s patent lawsuit is the company’s latest effort to shore up its place in the booming weight-loss drug market.",
    "url": "https://finnhub.io/api/news?id=c7b2e467660b66cbe42957f9a191fe0611089225e4fa0fd8ce07d68f99cbc85e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770664740,
      "headline": "Novo Nordisk Escalates Fight Against Hims & Hers",
      "id": 138693760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Danish drugmaker’s patent lawsuit is the company’s latest effort to shore up its place in the booming weight-loss drug market.",
      "url": "https://finnhub.io/api/news?id=c7b2e467660b66cbe42957f9a191fe0611089225e4fa0fd8ce07d68f99cbc85e"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Monday Afternoon",
    "summary": "Health care stocks were lower Monday afternoon, with the NYSE Health Care Index shedding 0.9% and th",
    "url": "https://finnhub.io/api/news?id=3928d4d38e3c2a3b104935098661bd9d207ff2d86f19ad8cf1a87312d41ebd8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770663041,
      "headline": "Sector Update: Health Care Stocks Decline Monday Afternoon",
      "id": 138693761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were lower Monday afternoon, with the NYSE Health Care Index shedding 0.9% and th",
      "url": "https://finnhub.io/api/news?id=3928d4d38e3c2a3b104935098661bd9d207ff2d86f19ad8cf1a87312d41ebd8f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout",
    "summary": "Lilly joins the growing list of big pharma companies hoping to see success from their acquired in vivo CAR-T programmes.",
    "url": "https://finnhub.io/api/news?id=c680fff82e43d05658a46fdd49554883c6dbc8c9d633afbae7077e0e6b112907",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770660011,
      "headline": "Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout",
      "id": 138693762,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly joins the growing list of big pharma companies hoping to see success from their acquired in vivo CAR-T programmes.",
      "url": "https://finnhub.io/api/news?id=c680fff82e43d05658a46fdd49554883c6dbc8c9d633afbae7077e0e6b112907"
    }
  },
  {
    "ts": null,
    "headline": "Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?",
    "summary": "Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.",
    "url": "https://finnhub.io/api/news?id=2e6e2c31c7d99ecb98435360bdb77a04712933d890ced71df1dcb1e2df87d123",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655800,
      "headline": "Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?",
      "id": 138608833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.",
      "url": "https://finnhub.io/api/news?id=2e6e2c31c7d99ecb98435360bdb77a04712933d890ced71df1dcb1e2df87d123"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655080,
      "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
      "id": 138693763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Novo Nordisk Sues Hims for Alleged Patent Infringement; Transocean to Acquire Valaris for $5.8 Billion",
    "summary": "All three major US stock indexes were up in late-morning trading Monday, as investors look ahead to",
    "url": "https://finnhub.io/api/news?id=a765e67ce1fd8eb5c0f00b1109eed7cbb8c458ea3540917646322e9c131b4b7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655002,
      "headline": "Top Midday Stories: Novo Nordisk Sues Hims for Alleged Patent Infringement; Transocean to Acquire Valaris for $5.8 Billion",
      "id": 138608834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Monday, as investors look ahead to",
      "url": "https://finnhub.io/api/news?id=a765e67ce1fd8eb5c0f00b1109eed7cbb8c458ea3540917646322e9c131b4b7d"
    }
  },
  {
    "ts": null,
    "headline": "Novo sues Hims & Hers despite Wegovy pill offering U-turn",
    "summary": "Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings.",
    "url": "https://finnhub.io/api/news?id=2e32c8d3d6a7fd35bb34be1040d3cc2652c8b8ed85029c998d0292dafda2ccbe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770654346,
      "headline": "Novo sues Hims & Hers despite Wegovy pill offering U-turn",
      "id": 138622384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo and Hims & Hers have continually locked horns over the legality of obesity drug offerings.",
      "url": "https://finnhub.io/api/news?id=2e32c8d3d6a7fd35bb34be1040d3cc2652c8b8ed85029c998d0292dafda2ccbe"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Just Popped",
    "summary": "Novo Nordisk just did Eli Lilly stock a huge favor.",
    "url": "https://finnhub.io/api/news?id=bc17889d2191b5d5c630f59bd292f0f449103c98747532bea0e7cfeb930b6d97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770653158,
      "headline": "Why Eli Lilly Stock Just Popped",
      "id": 138525998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk just did Eli Lilly stock a huge favor.",
      "url": "https://finnhub.io/api/news?id=bc17889d2191b5d5c630f59bd292f0f449103c98747532bea0e7cfeb930b6d97"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion",
    "summary": "Eli Lilly  shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said on Monday.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
    "url": "https://finnhub.io/api/news?id=02bac86869c1d41106201ab84b6bdd9f41e989480cf0ce97807b8d661111a0bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770653100,
      "headline": "Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion",
      "id": 138608836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said on Monday.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
      "url": "https://finnhub.io/api/news?id=02bac86869c1d41106201ab84b6bdd9f41e989480cf0ce97807b8d661111a0bf"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers stock crashes after FDA announces plans to take 'decisive steps' against GLP-1 compounds",
    "summary": "Hims & Hers stock fell sharply on Monday after the FDA said it would take steps to restrict the sale of its compounded versions of popular weight-loss drugs.",
    "url": "https://finnhub.io/api/news?id=7cc2ce627c09f9e44fcaae67e358dfeb6e6b26adf1d78649f56c29844af1baee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770652147,
      "headline": "Hims & Hers stock crashes after FDA announces plans to take 'decisive steps' against GLP-1 compounds",
      "id": 138514551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers stock fell sharply on Monday after the FDA said it would take steps to restrict the sale of its compounded versions of popular weight-loss drugs.",
      "url": "https://finnhub.io/api/news?id=7cc2ce627c09f9e44fcaae67e358dfeb6e6b26adf1d78649f56c29844af1baee"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Acquire Orna Therapeutics in $2.4 Billion Deal",
    "summary": "Eli Lilly (LLY) agreed to acquire Orna Therapeutics, a biotechnology company focused on engineering",
    "url": "https://finnhub.io/api/news?id=1ac40e7878dbe8a34283d584f5d5ec1129a11f67ec07444ad738ba00f2d82d4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770651819,
      "headline": "Eli Lilly to Acquire Orna Therapeutics in $2.4 Billion Deal",
      "id": 138514552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) agreed to acquire Orna Therapeutics, a biotechnology company focused on engineering",
      "url": "https://finnhub.io/api/news?id=1ac40e7878dbe8a34283d584f5d5ec1129a11f67ec07444ad738ba00f2d82d4b"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Plummets On FDA Crackdown, Novo Nordisk Lawsuit",
    "summary": "Hims stock crashed Monday after Novo Nordisk filed a lawsuit, claiming the online pharmacy is \"deceiving patients\" with its compounded drugs.",
    "url": "https://finnhub.io/api/news?id=5a91c086c344385896746d68fc35b048e47ee1e5d5ffba35a0a0ae33e2cbd05f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770650560,
      "headline": "Hims & Hers Plummets On FDA Crackdown, Novo Nordisk Lawsuit",
      "id": 138514553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims stock crashed Monday after Novo Nordisk filed a lawsuit, claiming the online pharmacy is \"deceiving patients\" with its compounded drugs.",
      "url": "https://finnhub.io/api/news?id=5a91c086c344385896746d68fc35b048e47ee1e5d5ffba35a0a0ae33e2cbd05f"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Plunges 15%, Novo Surges. Wegovy Battle Is Changing the Weight-Loss Drug Landscape.",
    "summary": "Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.",
    "url": "https://finnhub.io/api/news?id=e6a073c81b83768d1051b6025364f9f8778629ce1639f65ea712ced3409206f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770633240,
      "headline": "Hims & Hers Stock Plunges 15%, Novo Surges. Wegovy Battle Is Changing the Weight-Loss Drug Landscape.",
      "id": 138401387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.",
      "url": "https://finnhub.io/api/news?id=e6a073c81b83768d1051b6025364f9f8778629ce1639f65ea712ced3409206f2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?",
    "summary": "NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.",
    "url": "https://finnhub.io/api/news?id=7e49a298c9e3199cc8c3a29ff8c81240e874d782aa18ebc967e075f54440fe77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770648900,
      "headline": "Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?",
      "id": 138608837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.",
      "url": "https://finnhub.io/api/news?id=7e49a298c9e3199cc8c3a29ff8c81240e874d782aa18ebc967e075f54440fe77"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly buys Orna, Novo Nordisk sues Hims & Hers, Kyndryl plunges",
    "summary": "There are a number of stocks moving on the morning of Monday, Feb. 9, including Eli Lilly (LLY), Novo Nordisk (NVO), Hims & Hers (HIMS), and Kyndryl (KD). Morning Brief Anchor Julie Hyman breaks down some of the day's trending tickers. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=42ce75b7314b11e6c448f39c1868cc51a8dc49d7a52e4f915459dc34f252e08e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770647320,
      "headline": "Eli Lilly buys Orna, Novo Nordisk sues Hims & Hers, Kyndryl plunges",
      "id": 138514555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There are a number of stocks moving on the morning of Monday, Feb. 9, including Eli Lilly (LLY), Novo Nordisk (NVO), Hims & Hers (HIMS), and Kyndryl (KD). Morning Brief Anchor Julie Hyman breaks down some of the day's trending tickers. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=42ce75b7314b11e6c448f39c1868cc51a8dc49d7a52e4f915459dc34f252e08e"
    }
  },
  {
    "ts": null,
    "headline": "Unlocking Lilly (LLY) International Revenues: Trends, Surprises, and Prospects",
    "summary": "Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=3dd2f96b7c884364f55370ab48835f2d31f840af4a8ce81164a2bd394ccc2d51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770646506,
      "headline": "Unlocking Lilly (LLY) International Revenues: Trends, Surprises, and Prospects",
      "id": 138608838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=3dd2f96b7c884364f55370ab48835f2d31f840af4a8ce81164a2bd394ccc2d51"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?",
    "summary": "PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.",
    "url": "https://finnhub.io/api/news?id=6218bf24bf276aa438d0322878a67902e49fbb755d6b459d5558db730538d5d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770646260,
      "headline": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?",
      "id": 138514556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.",
      "url": "https://finnhub.io/api/news?id=6218bf24bf276aa438d0322878a67902e49fbb755d6b459d5558db730538d5d7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=f70be6fffb8ac6b2b4679c4882a667f7b089885b82959f4ae7837d0ae57aa2a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770645606,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 138514557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=f70be6fffb8ac6b2b4679c4882a667f7b089885b82959f4ae7837d0ae57aa2a5"
    }
  },
  {
    "ts": null,
    "headline": "China Warning Hampers Budding Stock Market Rally But Helps Gold; Pay Attention To Historic Takaichi Win",
    "summary": "China Warning",
    "url": "https://finnhub.io/api/news?id=0d19d134d4ea00548b69743d40598be3a26753e6facc1af9648e8464a37cbdf8",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770644984,
      "headline": "China Warning Hampers Budding Stock Market Rally But Helps Gold; Pay Attention To Historic Takaichi Win",
      "id": 138604628,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "\n\n\n\nChina Warning\n\n\n",
      "url": "https://finnhub.io/api/news?id=0d19d134d4ea00548b69743d40598be3a26753e6facc1af9648e8464a37cbdf8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion",
    "summary": "Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.",
    "url": "https://finnhub.io/api/news?id=cba010236c23503d79a4d1bf0293212ce2717a52eb5b3e4550c32a05d9cb8163",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770644220,
      "headline": "Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion",
      "id": 138514558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.",
      "url": "https://finnhub.io/api/news?id=cba010236c23503d79a4d1bf0293212ce2717a52eb5b3e4550c32a05d9cb8163"
    }
  },
  {
    "ts": null,
    "headline": "Monday's pre-market session: top gainers and losers in the S&P500 index",
    "summary": "As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
    "url": "https://finnhub.io/api/news?id=9ba08c785393a6f827af47c8ffb6308ea7e5d252204d76d31c92aac35341713d",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770644109,
      "headline": "Monday's pre-market session: top gainers and losers in the S&P500 index",
      "id": 138405186,
      "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
      "related": "LLY",
      "source": "ChartMill",
      "summary": "As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
      "url": "https://finnhub.io/api/news?id=9ba08c785393a6f827af47c8ffb6308ea7e5d252204d76d31c92aac35341713d"
    }
  },
  {
    "ts": null,
    "headline": "Super Bowl Commercials 2026: Complete List Of Ads, The Companies Behind Them And Who Won Over Fans",
    "summary": "The complete list of Super Bowl 2026 commercials from Super Bowl LX and the companies behind the ads.",
    "url": "https://finnhub.io/api/news?id=7b9f3d23019478a5139bd7b8c5db3b313b951d99f63bad37b6c02dbac5c96da9",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770643702,
      "headline": "Super Bowl Commercials 2026: Complete List Of Ads, The Companies Behind Them And Who Won Over Fans",
      "id": 138628238,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/09/Dhaka--Bangladesh---18-November--2025-Su.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "The complete list of Super Bowl 2026 commercials from Super Bowl LX and the companies behind the ads.",
      "url": "https://finnhub.io/api/news?id=7b9f3d23019478a5139bd7b8c5db3b313b951d99f63bad37b6c02dbac5c96da9"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Plunges. Its Weight Loss Drug Strategy Backfired.",
    "summary": "Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.",
    "url": "https://finnhub.io/api/news?id=d9622e736f7e496277f63004a50bcaab851c15f9d9a147f8db9593ace5ba23e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770642720,
      "headline": "Hims & Hers Stock Plunges. Its Weight Loss Drug Strategy Backfired.",
      "id": 138414693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy copycat.",
      "url": "https://finnhub.io/api/news?id=d9622e736f7e496277f63004a50bcaab851c15f9d9a147f8db9593ace5ba23e6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises. It’s Acquiring This Cell Therapy Company for $2.4 Billion.",
    "summary": "Eli Lilly  shares rose after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
    "url": "https://finnhub.io/api/news?id=897fc7d1fc2a9b5c1b358911fb66a1c7888a8001934d5d637a7e4674e940d399",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770640440,
      "headline": "Eli Lilly Stock Rises. It’s Acquiring This Cell Therapy Company for $2.4 Billion.",
      "id": 138414694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  shares rose after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
      "url": "https://finnhub.io/api/news?id=897fc7d1fc2a9b5c1b358911fb66a1c7888a8001934d5d637a7e4674e940d399"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Pays $350 Million Upfront in China Biotech Collaboration Deal",
    "summary": "Lilly partners with Innovent on new cancer and immune therapies, with potential milestones reaching $8.5 billion.",
    "url": "https://finnhub.io/api/news?id=94f3661f13dd8a21613eabd6e7d8a4fb9c3df6772b6e1ddc47aad5da7476fefd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770640189,
      "headline": "Eli Lilly Pays $350 Million Upfront in China Biotech Collaboration Deal",
      "id": 138414695,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly partners with Innovent on new cancer and immune therapies, with potential milestones reaching $8.5 billion.",
      "url": "https://finnhub.io/api/news?id=94f3661f13dd8a21613eabd6e7d8a4fb9c3df6772b6e1ddc47aad5da7476fefd"
    }
  },
  {
    "ts": null,
    "headline": "Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals",
    "summary": "Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.",
    "url": "https://finnhub.io/api/news?id=071d23d4f41c8036a65c5b087282398f3f8194d2be1e5f9138b47afe87e44d8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770639000,
      "headline": "Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals",
      "id": 138608839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.",
      "url": "https://finnhub.io/api/news?id=071d23d4f41c8036a65c5b087282398f3f8194d2be1e5f9138b47afe87e44d8c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to buy Orna Therapeutics for up to $2.4 billion",
    "summary": "Feb 9 () - ​Eli ‌Lilly will ‌acquire therapy developer ⁠Orna ‌Therapeutics for ‍up to $2.4 ​billion ‌in cash, the companies said ⁠on ​Monday.",
    "url": "https://finnhub.io/api/news?id=7f8c91cffc66f223457509204b8f835cf3b2057ca9dc59e7b789a126b8cd15d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770638982,
      "headline": "Lilly to buy Orna Therapeutics for up to $2.4 billion",
      "id": 138414696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Feb 9 () - ​Eli ‌Lilly will ‌acquire therapy developer ⁠Orna ‌Therapeutics for ‍up to $2.4 ​billion ‌in cash, the companies said ⁠on ​Monday.",
      "url": "https://finnhub.io/api/news?id=7f8c91cffc66f223457509204b8f835cf3b2057ca9dc59e7b789a126b8cd15d0"
    }
  },
  {
    "ts": null,
    "headline": "FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims",
    "summary": "The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.",
    "url": "https://finnhub.io/api/news?id=477fcbe5c4b300aedafdc9801852962b5970bf6e8cfb67111beb3bcafc1f2d2c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770638673,
      "headline": "FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims",
      "id": 138576320,
      "image": "https://image.cnbcfm.com/api/v1/image/108255920-1769106981439-gettyimages-2255813581-WEGOVY_PILLS.jpeg?v=1770655603&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill. ",
      "url": "https://finnhub.io/api/news?id=477fcbe5c4b300aedafdc9801852962b5970bf6e8cfb67111beb3bcafc1f2d2c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to acquire Orna Therapeutics to advance cell therapies",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.",
    "url": "https://finnhub.io/api/news?id=bb717d233e62b6195d5aeac76acce9fa186ea7aed96dffd0b2c2855345558a97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770638400,
      "headline": "Lilly to acquire Orna Therapeutics to advance cell therapies",
      "id": 138414697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.",
      "url": "https://finnhub.io/api/news?id=bb717d233e62b6195d5aeac76acce9fa186ea7aed96dffd0b2c2855345558a97"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill",
    "summary": "Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill following pressure from U.S. regulators.  Shares in Novo Nordisk jumped more than 7% in Denmark.  The stock also trades in the U.S. as an American depositary receipt with the ticker NVO.",
    "url": "https://finnhub.io/api/news?id=c9d37429eaa8a6df710d331d24735f0dd55ce3edc1da88dccdc2ea21fc7696b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770637612,
      "headline": "Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill",
      "id": 138414698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill following pressure from U.S. regulators.  Shares in Novo Nordisk jumped more than 7% in Denmark.  The stock also trades in the U.S. as an American depositary receipt with the ticker NVO.",
      "url": "https://finnhub.io/api/news?id=c9d37429eaa8a6df710d331d24735f0dd55ce3edc1da88dccdc2ea21fc7696b4"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Deepens Longtime Innovent Partnership",
    "summary": "Cancer and immunology programs take focus",
    "url": "https://finnhub.io/api/news?id=3344b88b660f1fc15dc636bf7fe67d0e0b0d4721d8aa7b99ffcbacd28cdfd0db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770637377,
      "headline": "Lilly Deepens Longtime Innovent Partnership",
      "id": 138414699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Cancer and immunology programs take focus",
      "url": "https://finnhub.io/api/news?id=3344b88b660f1fc15dc636bf7fe67d0e0b0d4721d8aa7b99ffcbacd28cdfd0db"
    }
  },
  {
    "ts": null,
    "headline": "Innovent and Lilly to advance new oncology and immunology medicines",
    "summary": "Innovent will receive an upfront payment of $350m under the agreement.",
    "url": "https://finnhub.io/api/news?id=3de3eeae01368501a865e5f87470113523a10c04012df8b87e6b1b28e754e1b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770634886,
      "headline": "Innovent and Lilly to advance new oncology and immunology medicines",
      "id": 138401186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Innovent will receive an upfront payment of $350m under the agreement.",
      "url": "https://finnhub.io/api/news?id=3de3eeae01368501a865e5f87470113523a10c04012df8b87e6b1b28e754e1b9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments",
    "summary": "Eli Lilly shares rise after announcing a $2.4 billion deal to buy Orna Therapeutics, strengthening its push into genetic medicine despite mixed markets.",
    "url": "https://finnhub.io/api/news?id=1e654df0a82e4c0054d06f240e16eb560abff812e8bff3467b6f5e0babb92eb6",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770631889,
      "headline": "Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments",
      "id": 138446881,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/09/Eli-Lilly.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Eli Lilly shares rise after announcing a $2.4 billion deal to buy Orna Therapeutics, strengthening its push into genetic medicine despite mixed markets.",
      "url": "https://finnhub.io/api/news?id=1e654df0a82e4c0054d06f240e16eb560abff812e8bff3467b6f5e0babb92eb6"
    }
  },
  {
    "ts": null,
    "headline": "FDA \"Swift Action\" Warning Sends Hims & Hers into a Tailspin",
    "summary": "Hims & Hers is facing intense selling pressure following a direct warning from the FDA targeting the large-scale marketing of compounded weight-loss drugs. This regulatory threat is striking at the heart of the company's newest growth engine, casting a shadow over its business model even as the broader market hits record highs.",
    "url": "https://finnhub.io/api/news?id=4f62c341cc74ce7ec7ab46116fa4ad9647e3f172b6a585be24d4e00829151eef",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770629444,
      "headline": "FDA \"Swift Action\" Warning Sends Hims & Hers into a Tailspin",
      "id": 138400828,
      "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_7_c18b96e841.webp",
      "related": "LLY",
      "source": "ChartMill",
      "summary": "Hims & Hers is facing intense selling pressure following a direct warning from the FDA targeting the large-scale marketing of compounded weight-loss drugs. This regulatory threat is striking at the heart of the company's newest growth engine, casting a shadow over its business model even as the broader market hits record highs.",
      "url": "https://finnhub.io/api/news?id=4f62c341cc74ce7ec7ab46116fa4ad9647e3f172b6a585be24d4e00829151eef"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=29be500a4dbe071111b2482c401ab5720285c62b5f285b462fd44969faa71f9a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770629113,
      "headline": "Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday",
      "id": 138413730,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/09/Los-Angeles--California---July-7-2025-El.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=29be500a4dbe071111b2482c401ab5720285c62b5f285b462fd44969faa71f9a"
    }
  },
  {
    "ts": null,
    "headline": "Here are 10 things to watch in the stock market Monday",
    "summary": "Shares of Eli Lilly and Novo Nordisk jumped in premarket trading after Hims & Hers said that the company will not sell its copycat weight-loss pill.",
    "url": "https://finnhub.io/api/news?id=fba2d7555bd7545c286cb67c2d4f394c171142bc024280a21b3f18fa141d94d4",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770628490,
      "headline": "Here are 10 things to watch in the stock market Monday",
      "id": 138574459,
      "image": "https://image.cnbcfm.com/api/v1/image/108247613-1767376953496-gettyimages-2253792451-US_STOCKS.jpeg?v=1770644405&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Shares of Eli Lilly and Novo Nordisk jumped in premarket trading after Hims & Hers said that the company will not sell its copycat weight-loss pill. ",
      "url": "https://finnhub.io/api/news?id=fba2d7555bd7545c286cb67c2d4f394c171142bc024280a21b3f18fa141d94d4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares rise as Hims abandons $49 weight-loss pill",
    "summary": "COPENHAGEN, Feb 9 () - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of ​a $49 weight-loss pill over the weekend, following legal threats from ‌Novo and the U. Hims introduced the compounded pill based on semaglutide - ‌a key ingredient in Novo's blockbuster drugs Wegovy and Ozempic - last Thursday, prompting pushback from the Danish drugmaker and regulatory authorities.",
    "url": "https://finnhub.io/api/news?id=fe1ee549fccaab4e8f9dc102185ff691cfab5247c5b4a42cc5b70335c4bd0c1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770628414,
      "headline": "Novo Nordisk shares rise as Hims abandons $49 weight-loss pill",
      "id": 138400487,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "COPENHAGEN, Feb 9 () - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of ​a $49 weight-loss pill over the weekend, following legal threats from ‌Novo and the U. Hims introduced the compounded pill based on semaglutide - ‌a key ingredient in Novo's blockbuster drugs Wegovy and Ozempic - last Thursday, prompting pushback from the Danish drugmaker and regulatory authorities.",
      "url": "https://finnhub.io/api/news?id=fe1ee549fccaab4e8f9dc102185ff691cfab5247c5b4a42cc5b70335c4bd0c1d"
    }
  },
  {
    "ts": null,
    "headline": "Deutsche Bank Maintains Buy on Eli Lilly and Co, Raises Price Target to $1285",
    "summary": "Deutsche Bank  analyst James Shin   maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $1200 to $1285.",
    "url": "https://finnhub.io/api/news?id=f92a7b162e8910c7c6af39e6eb1ba1a4b80eff3514b835b7840554550c5f84b8",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770626930,
      "headline": "Deutsche Bank Maintains Buy on Eli Lilly and Co, Raises Price Target to $1285",
      "id": 138446883,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Deutsche Bank  analyst James Shin   maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $1200 to $1285.",
      "url": "https://finnhub.io/api/news?id=f92a7b162e8910c7c6af39e6eb1ba1a4b80eff3514b835b7840554550c5f84b8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Agrees To Acquire Orna Therapeutics For Up To $2.4B",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.Orna",
    "url": "https://finnhub.io/api/news?id=b0946496ce23050545c410da0d3ef7a737fb5576dc6a0ddd2548ca3efe85523c",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770624313,
      "headline": "Eli Lilly Agrees To Acquire Orna Therapeutics For Up To $2.4B",
      "id": 138446884,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.Orna",
      "url": "https://finnhub.io/api/news?id=b0946496ce23050545c410da0d3ef7a737fb5576dc6a0ddd2548ca3efe85523c"
    }
  },
  {
    "ts": null,
    "headline": "Dow 50,000, Super Bowl 60, Meta's big week in court and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=ed31ddb93b484ed57dd09d40f45b63866ec8e3f315bc353d92799d85ea5cc28d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770624240,
      "headline": "Dow 50,000, Super Bowl 60, Meta's big week in court and more in Morning Squawk",
      "id": 138574150,
      "image": "https://image.cnbcfm.com/api/v1/image/108262786-17704095742026-02-06t202510z_1838434663_rc2igja75fzf_rtrmadp_0_usa-stocks.jpeg?v=1770409623&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=ed31ddb93b484ed57dd09d40f45b63866ec8e3f315bc353d92799d85ea5cc28d"
    }
  },
  {
    "ts": null,
    "headline": "Dow 50,000: A Milestone for the History Books Amidst an AI Spending War",
    "summary": "Wall Street hit a historic milestone as the Dow crossed 50,000, fueled by bargain hunters and a surge in chipmakers. The celebration is tempered by Amazon's massive $200 billion AI investment plan, which has sparked a debate over the long-term profitability of the tech sector's \"arms race.\"",
    "url": "https://finnhub.io/api/news?id=1ee4fbdbf0bf15f42ce97b81337385efd18c1feb5822673719ad1287f694d4cb",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770622617,
      "headline": "Dow 50,000: A Milestone for the History Books Amidst an AI Spending War",
      "id": 138400376,
      "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_6_6ca0787fb1.webp",
      "related": "LLY",
      "source": "ChartMill",
      "summary": "Wall Street hit a historic milestone as the Dow crossed 50,000, fueled by bargain hunters and a surge in chipmakers. The celebration is tempered by Amazon's massive $200 billion AI investment plan, which has sparked a debate over the long-term profitability of the tech sector's \"arms race.\"",
      "url": "https://finnhub.io/api/news?id=1ee4fbdbf0bf15f42ce97b81337385efd18c1feb5822673719ad1287f694d4cb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock plunges 27%",
    "summary": "Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.",
    "url": "https://finnhub.io/api/news?id=ac2818a5b38b5c585c327a0d3e0a3b3abd042b37ea0f7b5e0a5857ff8c285e79",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770620417,
      "headline": "Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock plunges 27%",
      "id": 138576324,
      "image": "https://image.cnbcfm.com/api/v1/image/108261299-1770641604537-108261299-17702146372026-02-04t141011z_1036041844_rc20fjavm80v_rtrmadp_0_novo-nordisk-results.jpg?v=1770641619&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages. ",
      "url": "https://finnhub.io/api/news?id=ac2818a5b38b5c585c327a0d3e0a3b3abd042b37ea0f7b5e0a5857ff8c285e79"
    }
  },
  {
    "ts": null,
    "headline": "Innovent Biologics Strikes Partnership Deal With Eli Lilly",
    "summary": "Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.",
    "url": "https://finnhub.io/api/news?id=5a436eda434b87e415f709b0734b0e20bf3c216894e5c53aaad3ef383c19a3f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770616620,
      "headline": "Innovent Biologics Strikes Partnership Deal With Eli Lilly",
      "id": 138399976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.",
      "url": "https://finnhub.io/api/news?id=5a436eda434b87e415f709b0734b0e20bf3c216894e5c53aaad3ef383c19a3f9"
    }
  }
]